HC Wainwright Reiterates “Buy” Rating for AEON Biopharma (NASDAQ:AEON)

AEON Biopharma (NASDAQ:AEON)‘s stock had its “buy” rating reissued by analysts at HC Wainwright in a research report issued on Monday, Benzinga reports. They currently have a $18.00 price target on the stock.

AEON Biopharma Trading Down 2.5 %

Shares of AEON opened at $1.59 on Monday. AEON Biopharma has a 52 week low of $1.38 and a 52 week high of $17.17. The stock has a fifty day moving average of $9.11 and a 200-day moving average of $7.60.

AEON Biopharma (NASDAQ:AEON) last announced its quarterly earnings results on Friday, March 29th. The company reported ($0.71) EPS for the quarter. Sell-side analysts predict that AEON Biopharma will post -1.18 earnings per share for the current fiscal year.

Hedge Funds Weigh In On AEON Biopharma

A hedge fund recently bought a new stake in AEON Biopharma stock. Formidable Asset Management LLC bought a new position in shares of AEON Biopharma, Inc. (NASDAQ:AEON) in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm bought 64,311 shares of the company’s stock, valued at approximately $360,000. Formidable Asset Management LLC owned about 0.72% of AEON Biopharma as of its most recent SEC filing. Institutional investors own 22.78% of the company’s stock.

AEON Biopharma Company Profile

AEON Biopharma, Inc, a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of both chronic and episodic migraine.